Patents
Literature
25 results about "Galactosyltransferase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Galactosyltransferase is a type of glycosyltransferase which catalyzes the transfer of galactose. An example is B-N-acetylglucosaminyl-glycopeptide b-1,4-galactosyltransferase. The biosynthesis of disaccharides, oligosaccharides and polysaccharides involves the action of hundreds of different glycosyltransferases. These enzymes catalyse the transfer of sugar moieties from activated donor molecules to specific acceptor molecules, forming glycosidic bonds. A classification of glycosyltransferases using nucleotide diphospho-sugar, nucleotide monophospho-sugar and sugar phosphates (EC 2.4.1.-) and related proteins into distinct sequence based families has been described. This classification is available on the CAZy (Carbohydrate-Active EnZymes) web site. The same three-dimensional fold is expected to occur within each of the families. Because 3-D structures are better conserved than sequences, several of the families defined on the basis of sequence similarities may have similar 3-D structures and therefore form 'clans'.
Beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H and application thereof
PendingCN121852347AIncrease enzyme activityImprove thermal stabilityBacteriaMicroorganism based processesLactoseTetrasaccharide
The invention discloses a beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H and an application thereof, and belongs to the technical field of functional enzymes. And the amino acid sequence of the beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H is as shown in SEQ ID NO. 3. The invention further discloses the application of the beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H in the preparation of lactose-N-tetrasaccharide. According to the invention, 1, 3-galactosyl transferase Pm beta 3GalT is subjected to mutation modification to obtain a mutant enzyme, and compared with a wild enzyme, the enzyme activity of the mutant enzyme is improved by 157.21% and is obviously improved, and the thermal stability and alkali resistance are also obviously improved. The beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H disclosed by the invention has important theoretical value and application value on the industrial production of LNT (Lipoxystrobin).
Owner:OCEAN UNIV OF CHINA
A plasmid-free genetically engineered strain for high-yield lactosyl-n-tetrasaccharide based on key enzyme screening and modification and application thereof
This invention discloses a high-yield lactyl-3-4 ...5-4-4-4-4-4- N This invention relates to plasmid-free genetically engineered strains of tetrasaccharides and their applications, belonging to the field of microbial genetic engineering. The invention screened strains with higher activity. β -1,3-galactosyltransferase gene PmgalT Computer-aided enzyme function modification was used to achieve a shake-flask yield of 10.05 g / L for the constructed mutant. Subsequently, genome integration was performed... breast Multi-copy integration PmgalT * V27I / V39I / Y147F ‑galE‑galU A plasmid-free strain was constructed, enabling it to grow in shake flasks with lactoyl- N The yield of tetrasaccharides reached 14.4 g / L. Using glucose as the sole carbon source, the highest yield of 68.19 g / L was achieved at 64.5 h; using glycerol as the sole carbon source, the highest yield of 62.88 g / L was achieved at 60.5 h, providing a basis for its industrial production.
Owner:JIANGNAN UNIV
Preparation method and application of alpha-2, 3-sialic acid glycosyl transferase mediated sugar chain fixed-point coupling antibody drug conjugate
ActiveCN121271994AImmunoglobulinsPharmaceutical non-active ingredientsAntiendomysial antibodiesEfficacy
The invention provides a preparation method of an alpha-2, 3 sialic acid glycosyl transferase mediated sugar chain fixed-point coupling antibody drug conjugate, which comprises the following steps: S1, dissolving an antibody, adding UDP-Gal, Mn < 2 + > and beta-1, 4 galactosyl transferase for reaction, and purifying after reaction to obtain an antibody I with galactose at the tail end of a sugar chain; s2, dissolving the antibody I, adding an azide-modified CMP sialic acid derivative, alpha-2, 3 sialic acid glycosyltransferase and alkaline phosphatase for reaction, and purifying after reaction to obtain an antibody II of which the tail end of a carbohydrate chain is connected with the sialic acid derivative; s3, dissolving toxin molecules in DMSO, adding the dissolved toxin molecules into the antibody II for reaction, and performing ultrafiltration after the reaction to obtain ADC molecules; or the ADC molecule is directly prepared by adopting a one-pot enzyme method. The screened ST3Gal3 is used for preparing the carbohydrate chain fixed-point coupling ADC, the DAR value is controllable, batch-to-batch stability is achieved, uniformity is high, repeatability is high, quality control and CMC are better, and then the drug effect of the ADC can be better improved.
Owner:WUHAN TANGZHI PHARM CO LTD
Beta 1, 4-galactosyl transferase Ha beta 4GalT-I211V and application thereof in synthesis of pLNnH
The invention discloses beta 1, 4-galactosyl transferase Ha beta 4GalT-I211V and application of the beta 1, 4-galactosyl transferase Ha beta 4GalT-I211V in synthesis of pLNnH, and belongs to the technical field of functional enzymes. And the amino acid sequence of the beta 1, 4-galactosyl transferase Ha beta 4GalT-I211V is as shown in SEQ ID NO. 3. The invention further discloses the application of the beta 1, 4-galactosyl transferase Ha beta < 4 > GalT-I211V in the synthesis of pLNnH. The beta 1, 4-galactosyl transferase Ha beta 4GalT-I211V provided by the invention is obtained by mutation modification, and the beta 1, 4-galactosyl transferase Ha beta 4GalT-I211V can be used for preparing straight-chain lactoyl-N-neohexasaccharide by taking UDP-galactose as a donor and straight-chain lactoyl-N-pentasaccharide as a receptor. The beta 1, 4-galactosyl transferase Ha beta 4GalT-I211V disclosed by the invention has a wide application prospect, and is of great significance to industrial preparation of linear-chain lactyl-N-neohexaose.
Owner:OCEAN UNIV OF CHINA
Beta 1,4-galactosyltransferase Habetagalt-s233p and its use in the synthesis of lnnt
The application discloses a beta 1,4-galactosyltransferase Ha beta 4GalT-S233P and application thereof in synthesis of LNnT, and belongs to the technical field of functional enzymes. The amino acid sequence of the beta 1,4-galactosyltransferase Ha beta 4GalT-S233P is shown as SEQ ID NO. 3. The application discloses the application of the beta 1,4-galactosyltransferase Ha beta 4GalT-S233P in synthesis of LNnT. The beta 1,4-galactosyltransferase Ha beta 4GalT-S233P is obtained by modification of the beta 1,4-galactosyltransferase Ha beta 4GalT, has higher glycosyltransfer activity, and the conversion rate of synthesis of LNnT can reach 99.80%. The application lays a foundation for metabolic engineering of Escherichia coli for production of LNnT.
Owner:OCEAN UNIV OF CHINA
Genetically engineered bacteria for producing lacto-n-neotetraose and construction method and application thereof
The application provides a genetically engineered bacterium for producing lactose-N-neotetraose, a construction method and application thereof. The genetically engineered bacterium satisfies the following conditions: (1) exogenous expression of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase; (2) overexpression of galactoside permease and UDP-galactose-4-epimerase; and (3) no expression or weakened expression of setA transporter protein. The applicant of the application finds through research that exogenous introduction of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase in the genetically engineered bacterium, enhancement of the expression amount of galactoside permease and UDP-galactose-4-epimerase in the genome, and reduction of the expression amount of setA transporter protein can effectively reduce the residual amount of LNT II in the LNnT synthesis pathway and improve the fermentation yield of LNnT.
Owner:CABIO BIOTECH (WUHAN) CO LTD
Arrhythmogenic cardiomyopathy lipid pathogenesis
PCT designated stageWO2026085157A1Cosmetic preparationsToilet preparationsMyocardial fiberGlycosphingolipid
Arrhythmogenic cardiomyopathy (ACM) is a familial heart disease characterized by progressive myocardial fibrofatty infiltration. Compositions in the treatment of fibrofatty accumulation and its pathogenesis in ACM include activators of glycosphingolipid (GSL) glycosyltransferase, β-1,4-galactosyltransferase- V (β-1,4-GalT-V).
Owner:JOHNS HOPKINS UNIVERSITY
A method for in vitro synthesis of natural H11 glycopeptides from Haemonchus contortus
This invention discloses a method for in vitro synthesis of natural H11 glycopeptides from *Haemaphysalis contortus*, belonging to the field of biomedicine. The method includes the following steps: preparing a glycosyl donor compound using sialic acid glycopeptide SGP as a raw material; activating the glycosyl donor to a glycooxazoline; transglycosylation of the glycooxazoline with an H11 glycopeptide chain carrying acetylglucosamine at the N site to obtain the glycopeptide compound; catalyzing the glycopeptide compound with core fucosyltransferase 8, *Haemaphysalis contortus*-derived galactosyltransferase 1, β-1,4-galactosyltransferase, and fucosyltransferase to obtain corresponding glycosyl modifications from the donor, yielding a natural *Haemaphysalis contortus* H11 glycopeptide containing an LDNF structure and a *Gal(β1,4)Fuc* nematode-specific epitope. This invention can accurately mimic the nematode-specific glycosylation modification of natural H11, with high product uniformity, and can provide an antigen source for vaccine development for *Haemaphysalis contortus* disease.
Owner:HUAZHONG AGRI UNIV
Non-human animals with humanized FC epsilon receptors that lack functional alpha-1, 3-galactosyltransferase (GGTA1)
Provided herein are genetically modified rodents (e.g., mice or rats) with a human or humanized Fc epsilon receptor 1 alpha (FcεR1α) that do not express a functional α-1,3, -galactosyltransferase (GGTA1). Also provided herein are methods of making and / or using such rodents, cells from such rodents, and ES cells comprising the same genetic modifications.
Owner:REGENERON PHARMACEUTICALS INC
Application of β-1,4-galactosyltransferase 1 and its inhibitors in the preparation of drugs for treating acute and chronic liver diseases
ActiveCN116794308Bacute liver failure remissionEffective reliefDigestive systemMicrobiological testing/measurementHepatic inflammationChronic hepatitis
This invention discloses the application of β-1,4-galactosyltransferase 1 and its inhibitors in liver diseases, particularly acute liver injury and liver failure. The application of β-1,4-galactosyltransferase 1 and its inhibitors in acute liver injury and liver failure provides the correlation between β-1,4-galactosyltransferase 1 and acute liver injury and liver failure, confirming that inhibiting the activity of β-1,4-galactosyltransferase 1 can alleviate acute liver injury and liver failure. β-1,4-galactosyltransferase 1 can serve as a drug target for screening acute and chronic hepatitis, liver injury, fatty liver, liver fibrosis, and acute and chronic liver failure. This invention also confirms the alleviating effect of β-1,4-galactosyltransferase 1 inhibitors on acute liver failure. β-1,4-galactosyltransferase 1 inhibitors improve acute liver failure by reducing the enzyme activity or protein expression of β-1,4-galactosyltransferase 1.
Owner:CHINA PHARM UNIV
Preparation method and application of a glycosyl site-directed conjugated antibody drug conjugate
PendingCN122256264AOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody conjugatePharmaceutical drug
The application belongs to the technical field of biological medicine, and discloses a preparation method and application of an antibody drug conjugate with site-specific glycosyl coupling. The application discloses a recombinant cell containing a nucleic acid molecule encoding trastuzumab, and the FUT8 gene and the B4GALT1 gene are deleted. The application provides a recombinant cell which can efficiently and stably prepare trastuzumab with a uniform A2 glycosylation type. Based on the trastuzumab, 2, 4 or 6 azido groups can be introduced at specific sites of the antibody by using alpha 1, 6-fucosyltransferase and / or beta 1, 4-galactosyltransferase, and a toxin molecule is further connected, so that an antibody conjugate with uniformity and DAR value = 2, DAR value = 4 or DAR value = 6 is prepared.
Owner:SUN YAT SEN UNIV
Use of b4galt1 in preparation of drugs against mycobacterium tuberculosis infection
ActiveCN115957312BReduce bacterial loadReduce the ability to phagocytose bacteriaAntibacterial agentsPeptide/protein ingredientsDrug targetMycobacterium
The application discloses application of beta 1,4-galactosyltransferase 1 (B4GALT1) in preparation of a medicine for resisting mycobacterium tuberculosis infection and belongs to the technical field of biotechnology. The application first determines that a host functional protein B4GALT1 can improve the serum IgG galactosylation level, promote macrophage phagocytosis and killing of mycobacterium tuberculosis, and reduce the bacterial load. The B4GALT1 can be used as a new potential medicine for resisting tuberculosis infection. The application achievement can provide a new tool and thought for clinical treatment of tuberculosis, especially has a broad prospect in development and clinical application of an anti-tuberculosis medicine and can be directly applied to the scientific research field. The application has important application value for obtaining a new drug target for resisting tuberculosis and screening a new medicine.
Owner:WUHAN UNIV
Gmsgt2 gene and mutant and application thereof related to plant height and branch development
ActiveCN118726381Bsmall branchesimportant breeding valueClimate change adaptationPlant peptidesBiotechnologyGermplasm
This invention belongs to the field of biotechnology, specifically relating to the GmSGT2 gene and its mutants related to plant height and branching development, and their applications. Specifically, this invention obtains a soybean mutant with fewer branches and reduced plant height through EMS mutagenesis, and locates the target gene as the GmSGT2 gene of soybean variety 'He Dou 12' using map-based cloning technology. Searching reveals that this gene encodes soybean saponin B glucuronide galactosyltransferase, which can galactosylate soybean saponin B monoglucuronide, thus affecting soybean plant height and reducing branching. Therefore, the gmsgt2 mutant can be used to breed dwarf, high-yielding soybean varieties, which is of profound significance in breeding ideal soybean plant architecture and research on important agronomic traits. It has broad application prospects and high research value for understanding the regulation mechanism of soybean plant height and branching, improving the soybean breeding process, and can provide excellent germplasm resources for regulating soybean dense planting and high-yield breeding.
Owner:SHANDONG UNIV
Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided.
Owner:REVIVICOR INC
Beta 1, 4-galactosyl transferase Ha beta 4GalT-S233P and application thereof in synthesis of LNnT
The invention discloses beta 1, 4-galactosyl transferase Ha beta 4GalT-S233P and application of the beta 1, 4-galactosyl transferase Ha beta 4GalT-S233P in synthesis of LNnT, and belongs to the technical field of functional enzymes. And the amino acid sequence of the beta 1, 4-galactosyl transferase Ha beta 4GalT-S233P is as shown in SEQ ID NO. 3. The invention further discloses the application of the beta 1, 4-galactosyl transferase Ha beta < 4 > GalT-S233P in the synthesis of LNnT. The beta 1, 4-galactosyl transferase Ha beta 4GalT-S233P provided by the invention is obtained by modifying the beta 1, 4-galactosyl transferase Ha beta 4GalT, and has higher transglycosylation activity, and the conversion rate of the synthesized LNnT can reach 99.80%. The invention lays a foundation for producing LNnT by transforming escherichia coli through metabolic engineering.
Owner:OCEAN UNIV OF CHINA
Multitransgenic pigs comprising ten genetic modifications for xenotransplantation
The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.
Owner:REVIVICOR INC
Recombinant escherichia coli for efficiently preparing high-purity sialyllactose-n-tetrasaccharide a, and preparation method and application thereof
ActiveCN121472117BIncrease productionhigh purityBacteriaMicroorganism based processesBiotechnologyEscherichia coli
The application provides a construction method and application of recombinant escherichia coli for efficiently preparing high-purity sialyllactose-N-tetraose a. The application precisely integrates genes encoding beta-1,3-N-acetylglucosamine glycosyltransferase, beta-1,3-galactosyltransferase and alpha-2,3-sialic acid glycosyltransferase in the genome of escherichia coli BL21 (DE3), knocks out endogenous competitive metabolic genes, and optimizes the metabolic pathways of precursor substances UDP-acetylglucosamine, UDP-galactose and CMP-N-acetylneuraminic acid, effectively reduces the generation of non-target byproducts including lactose-N-triose, lactose-N-tetraose and 3'-sialyllactose, and successfully constructs a recombinant chassis strain capable of efficiently producing high-purity sialyllactose-N-tetraose a. Fermentation culture of the constructed engineering bacteria can efficiently prepare high-purity sialyllactose-N-tetraose a under the premise of guaranteeing biosafety, and is suitable for the production demand in the food field.
Owner:TIANJIN HESHENG BIOTECHNOLOGY CO LTD
Expression system for glycoengineered antigens
PCT designated stageWO2026115038A1PeptidesAntigen/adjuvant combination ingredientsFucosylationAntigen
The present invention relates to an expression system for the extracellular production of recombinant tri-fucosylated N-glycoproteins in insect cells. The invention also relates to an expression cassette comprising a glyco-module comprising polynucleotide sequences of a nematode galactosyltransferase, fucosyltransferase, and mannosidase; and a polynucleotide sequence encoding one or more tri-fucosylated N-glycoproteins derived from a nematode; a recombinant baculovirus comprising said expression cassette, a method for producing said tri-fucosylated N-glycoproteins in transfected insect cells, and a transfected insect cell. The invention also relates to an immunological composition comprising said tri-fucosylated N-glycoproteins, which can be administered to ruminants to induce protective anti-nematode immunity.
Owner:VETERINARMEDIZINISCHE UNIV WIEN +2
Immunotherapy using GGTA and nap
PCT designated stageWO2026068773A1Tumor rejection antigen precursorsPeptide/protein ingredientsImmune therapyViral vector
The present invention relates to a vector, such as a viral vector, comprising a first nucleic acid sequence encoding a glycosyltransferase (such as a galactosyltransferase), an enzymatically active variant or truncated form thereof; and a second nucleic acid sequence encoding a Helicobacter pylori neutrophil-activating protein (NAP), an immunologically equivalent variant or fragment thereof. The invention also relates to a vector system, an isolated cell population, a polynucleotide and relating gene therapy systems comprising said first and said second nucleic acid sequence. Related methods, kits, pharmaceutical compositions and medical uses, in particular, in the treatment of cancer, such as pancreatic cancer, are also disclosed.
Owner:REPUDIO AB
Recombinant alpha-1,3-galactosyltransferase and methods of making and using the same
The present application relates to the technical field of molecular biology, in particular to a kind of recombinant alpha-1,3-galactosyltransferase and its preparation method and application.The recombinant protein is recombinant alpha-1,3-galactosyltransferase, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO.1.The sequence of alpha-GT gene of the present application realizes the aggregation of high concentration of protein in cell after expression in engineering bacteria, but at the same time, it does not occur with the combination of cell membrane, and this characteristic helps to improve the yield of target protein in the fermentation process of engineering bacteria, reduces the operation difficulty in the process of purification, improves protein purity and activity.
Owner:SHANGHAI MINGDA BIOTECH CO LTD
Chloroplast-localized cotton drought-resistant related protein galactosyl transferase GhNGalT1 and application thereof
PendingCN121852349ABroaden transferase functionImprove drought resistanceTransferasesFermentationBiotechnologyGenetics
The invention discloses a cotton drought-resistant related protein galactosyl transferase GhNGalT1 positioned in chloroplast and application of the cotton drought-resistant related protein galactosyl transferase GhNGalT1. According to the invention, a galactosyl transferase gene GhNGalT1 which is induced by ABA and is positioned in chloroplast in cotton is cloned and identified for the first time, a new potential drought-resistant regulation pathway of ABA signal-GhNGalT1-chloroplast function is disclosed, and the understanding of the plant glycosyl transferase function, especially the abiotic stress response function of the plant glycosyl transferase gene in chloroplast, is broadened. Functional verification shows that GhNGalT1 is a positive regulation factor for drought resistance of cotton. Overexpression of the gene can significantly enhance the drought resistance of cotton, and silence or knockout of the gene causes the cotton to be more sensitive to drought. The GhNGalT1 gene has an important application value in main varieties of cotton, can be used for molecular design breeding and cultivation of new varieties of drought-resistant, water-saving, stable-yield and high-quality cotton, and has practical significance for guaranteeing the safety of cotton production in China.
Owner:INST OF COTTON RES CHINESE ACAD OF AGRI SCI +2
Multitransgenic pigs comprising ten genetic modifications for xenotransplantation
The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.
Owner:REVIVICOR INC
Xenogeneic antigen presenting cells and uses thereof
PCT designated stageWO2026085177A1Mammal material medical ingredientsFermentationPharmaceutical drugCancer therapy
The present disclosure relates to methods for treating a tumor in a subject via administering (e.g., by intratumoral injection) a composition comprising antigen presenting cells obtained from a species that is different than the subject, i.e., xenogeneic antigen presenting cells. The source of such xenogeneic antigen presenting cells could be one or more swine (e.g, a swine that expresses alpha- 1,3 galactosyltransferase). The present disclosure also relates to methods of treating tumors via administering the xenogeneic antigen presenting cells in combination with other anti-cancer therapies. Furthermore, the present disclosure relates to pharmaceutical compositions comprising xenogeneic antigen presenting cells.
Owner:ONCONEX LLC +2
Methods for the production of cytoprotective asialo-erythropoietin in plants and its purification from plant tissues
The present invention provides methods for the high-level production of recombinant human erythropoietin (rhuEPO) derivative, asialoerythropoietin (asialo-rhuEPO), in plants. The methods for producing asialo-rhuEPO comprise making a plant or at least one plant cell that comprises a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding a human erythropoieting fusion protein and a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding N-glycosylation modification enzyme, particularly a mammalian β1, 4-galactosyltransferase. The present invention further provides plants, plant cells, and seeds that have been genetically modified to produce high levels of asialo-rhuEPO. Additionally, provided are methods for purifying asialo-rhuEPO from plant tissues. Such methods comprise removing chlorophyll and / or RuBisCO protein from an aqueous extract of plant tissue comprising asialo-rhuEPO, binding the asialo-rhuEPO in the extract to an immune affinity column, and eluting the bound asialo-rhuEPO from immune affinity column.
Owner:NORTH CAROLINA CENTRAL UNIVERSITY
Recombinant escherichia coli for efficiently preparing high-purity sialic acid lactose-N-tetrasaccharide as well as preparation method and application of recombinant escherichia coli
The invention provides a construction method and application of recombinant escherichia coli for efficiently preparing high-purity sialic acid lactose-N-tetrasaccharide a. According to the invention, genes for coding beta-1, 3-N-acetyl glucosamino transferase, beta-1, 3-galactosyl transferase and alpha-2, 3-sialic acid glycosyl transferase are accurately integrated in an escherichia coli BL21 (DE3) genome, and endogenous competitive metabolism genes are knocked out, so that the escherichia coli BL21 (DE3) gene is obtained; the metabolic pathways of precursor substances, namely UDP-acetyl glucosamine, UDP-galactose and CMP-N-acetylneuraminic acid, are systematically optimized; the generation of non-target byproducts including lactose-N-trisaccharide, lactose-N-tetrasaccharide and 3 '-sialic acid lactose is effectively reduced, and the recombinant chassis strain capable of efficiently producing high-purity sialic acid lactose-N-tetrasaccharide a is successfully constructed. The constructed engineering bacteria are used for fermentation culture, so that high-purity sialic acid lactose-N-tetrasaccharide a can be efficiently prepared on the premise of guaranteeing biological safety, and the production requirements in the food field are met.
Owner:TIANJIN HESHENG BIOTECHNOLOGY CO LTD